{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:27:33Z","timestamp":1792218453725,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/gt.2010.87","type":"journal-article","created":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T16:12:33Z","timestamp":1278000753000},"page":"1042-1051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors"],"prefix":"10.1038","volume":"17","author":[{"given":"M","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R G","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,1]]},"reference":[{"key":"BFgt201087_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225\u2013249.","journal-title":"CA Cancer J Clin"},{"key":"BFgt201087_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.2007.13.1912","volume":"26","author":"CP Belani","year":"2008","unstructured":"Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 468\u2013473.","journal-title":"J Clin Oncol"},{"key":"BFgt201087_CR3","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.2007.12.2689","volume":"26","author":"GR Blumenschein Jr","year":"2008","unstructured":"Blumenschein Jr GR, Khuri FR, von PJ, Gatzemeier U, Miller Jr WH, Jotte RM et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: II SPIRIT. J Clin Oncol 2008; 26: 1879\u20131885.","journal-title":"J Clin Oncol"},{"key":"BFgt201087_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(08)70261-4","volume":"9","author":"K Kubota","year":"2008","unstructured":"Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008; 9: 1135\u20131142.","journal-title":"Lancet Oncol"},{"key":"BFgt201087_CR5","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1200\/JCO.2007.12.2614","volume":"26","author":"R Ramlau","year":"2008","unstructured":"Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M et al. Randomized phase III trial comparing bexarotene (L1069-49)\/cisplatin\/vinorelbine with cisplatin\/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 2008; 26: 1886\u20131892.","journal-title":"J Clin Oncol"},{"key":"BFgt201087_CR6","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von PJ, Biesma B, Vansteenkiste J, Manegold C et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543\u20133551.","journal-title":"J Clin Oncol"},{"key":"BFgt201087_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2008.17.1405","volume":"27","author":"PM Fidias","year":"2009","unstructured":"Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591\u2013598.","journal-title":"J Clin Oncol"},{"key":"BFgt201087_CR8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","volume":"373","author":"R Pirker","year":"2009","unstructured":"Pirker R, Pereira JR, Szczesna A, von PJ, Krzakowski M, Ramlau R et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525\u20131531.","journal-title":"Lancet"},{"key":"BFgt201087_CR9","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182\u20131186.","journal-title":"N Engl J Med"},{"key":"BFgt201087_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara N . VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795\u2013803.","journal-title":"Nat Rev Cancer"},{"key":"BFgt201087_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J . The biology of VEGF and its receptors. Nat Med 2003; 9: 669\u2013676.","journal-title":"Nat Med"},{"key":"BFgt201087_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581\u2013611.","journal-title":"Endocr Rev"},{"issue":"Suppl 3","key":"BFgt201087_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000088479","volume":"69","author":"N Ferrara","year":"2005","unstructured":"Ferrara N . VEGF as a therapeutic target in cancer. Oncology 2005; 69 (Suppl 3): 11\u201316.","journal-title":"Oncology"},{"key":"BFgt201087_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cardiores.2004.12.002","volume":"65","author":"T Tammela","year":"2005","unstructured":"Tammela T, Enholm B, Alitalo K, Paavonen K . The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65: 550\u2013563.","journal-title":"Cardiovasc Res"},{"key":"BFgt201087_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L . VEGF receptor signaling\u2014in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359\u2013371.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFgt201087_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391\u2013400.","journal-title":"Nat Rev Drug Discov"},{"key":"BFgt201087_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W . Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328\u2013335.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFgt201087_CR18","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ, Chisholm V, Meng YG, Krummen L et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593\u20134599.","journal-title":"Cancer Res"},{"key":"BFgt201087_CR19","first-page":"3369","volume":"61","author":"CJ Sweeney","year":"2001","unstructured":"Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369\u20133372.","journal-title":"Cancer Res"},{"key":"BFgt201087_CR20","first-page":"3226","volume":"8","author":"WD Fox","year":"2002","unstructured":"Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002; 8: 3226\u20133231.","journal-title":"Clin Cancer Res"},{"key":"BFgt201087_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1089\/hum.2007.109","volume":"19","author":"M Watanabe","year":"2008","unstructured":"Watanabe M, Boyer JL, Hackett NR, Qiu J, Crystal RG . Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice. Hum Gene Ther 2008; 19: 300\u2013310.","journal-title":"Hum Gene Ther"},{"key":"BFgt201087_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427\u2013434.","journal-title":"N Engl J Med"},{"key":"BFgt201087_CR23","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335\u20132342.","journal-title":"N Engl J Med"},{"key":"BFgt201087_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792\u2013799.","journal-title":"J Clin Oncol"},{"key":"BFgt201087_CR25","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542\u20132550.","journal-title":"N Engl J Med"},{"key":"BFgt201087_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227\u20131234.","journal-title":"J Clin Oncol"},{"key":"BFgt201087_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1089\/hum.2008.169","volume":"20","author":"M Watanabe","year":"2009","unstructured":"Watanabe M, Boyer JL, Crystal RG . Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum Gene Ther 2009; 20: 598\u2013610.","journal-title":"Hum Gene Ther"},{"key":"BFgt201087_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ymthe.2005.09.003","volume":"13","author":"BP De","year":"2006","unstructured":"De BP, Heguy A, Hackett NR, Ferris B, Leopold PL, Lee J et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 2006; 13: 67\u201376.","journal-title":"Mol Ther"},{"key":"BFgt201087_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/08977199209023937","volume":"7","author":"KJ Kim","year":"1992","unstructured":"Kim KJ, Li B, Houck K, Winer J, Ferrara N . The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7: 53\u201364.","journal-title":"Growth Factors"},{"key":"BFgt201087_CR30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","volume":"65","author":"HP Gerber","year":"2005","unstructured":"Gerber HP, Ferrara N . Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671\u2013680.","journal-title":"Cancer Res"},{"key":"BFgt201087_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/sj.cgt.7700376","volume":"8","author":"S BenAmmar-Ceccoli","year":"2001","unstructured":"BenAmmar-Ceccoli S, Humblot S, Crouzier R, Acres B, Kieny MP, Herlyn D et al. Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth. Cancer Gene Ther 2001; 8: 815\u2013826.","journal-title":"Cancer Gene Ther"},{"key":"BFgt201087_CR32","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/blood.V97.5.1370","volume":"97","author":"JM Timmerman","year":"2001","unstructured":"Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R . Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 2001; 97: 1370\u20131377.","journal-title":"Blood"},{"key":"BFgt201087_CR33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nbt1087","volume":"23","author":"J Fang","year":"2005","unstructured":"Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584\u2013590.","journal-title":"Nat Biotechnol"},{"key":"BFgt201087_CR34","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1158\/1078-0432.CCR-06-0746","volume":"12","author":"M Jiang","year":"2006","unstructured":"Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 2006; 12: 6179\u20136185.","journal-title":"Clin Cancer Res"},{"key":"BFgt201087_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/cgt.2008.68","volume":"16","author":"DT Ho","year":"2009","unstructured":"Ho DT, Wykoff-Clary S, Gross CS, Schneider D, Jin F, Kretschmer PJ et al. Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer Gene Ther 2009; 16: 184\u2013194.","journal-title":"Cancer Gene Ther"},{"key":"BFgt201087_CR36","first-page":"115","volume-title":"Gene and Cell Therapy","author":"BJ Carter","year":"2008","unstructured":"Carter BJ, Burstein H, Peluso RW . Adeno-associated virus and AAV vectors for gene delivery. In: NSTempleton (ed) Gene and Cell Therapy. CRC Press: Boca Raton, 2008, pp 115."},{"key":"BFgt201087_CR37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","volume":"38","author":"DM McCarty","year":"2004","unstructured":"McCarty DM, Young Jr SM, Samulski RJ . Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004; 38: 819\u2013845.","journal-title":"Annu Rev Genet"},{"key":"BFgt201087_CR38","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.ymthe.2004.08.022","volume":"10","author":"B De","year":"2004","unstructured":"De B, Heguy A, Leopold PL, Wasif N, Korst RJ, Hackett NR et al. Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin. Mol Ther 2004; 10: 1003\u20131010.","journal-title":"Mol Ther"},{"key":"BFgt201087_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.mt.6300344","volume":"16","author":"BP De","year":"2008","unstructured":"De BP, Hackett NR, Crystal RG, Boyer JL . Rapid\/sustained anti-anthrax passive immunity mediated by co-administration of Ad\/AAV. Mol Ther 2008; 16: 203\u2013209.","journal-title":"Mol Ther"},{"key":"BFgt201087_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.virol.2008.04.016","volume":"378","author":"D Skaricic","year":"2008","unstructured":"Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG et al. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology 2008; 378: 79\u201385.","journal-title":"Virology"},{"key":"BFgt201087_CR41","first-page":"133","volume-title":"Pleural Diseases","author":"RW Light","year":"2007","unstructured":"Light RW . Pleural effusions related to metastatic malignancies. In: RW Light (ed) Pleural Diseases. Lippincott Williams & Wilkins: Philadelphia, 2007, pp 133."},{"key":"BFgt201087_CR42","first-page":"306","volume-title":"Pleural Diseases","author":"RW Light","year":"2007","unstructured":"Light RW . Pneumothorax. In: RW Light (ed) Pleural Diseases. Lippincott Williams & Wilkins: Philadelphia, 2007, pp 306."},{"key":"BFgt201087_CR43","unstructured":"Baca M, Wells JA, inventors, I. Genentech, assignee. Anti-VEGF antibodies. USA. Patent no. 6,884,879 1997."},{"key":"BFgt201087_CR44","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","volume":"72","author":"X Xiao","year":"1998","unstructured":"Xiao X, Li J, Samulski RJ . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224\u20132232.","journal-title":"J Virol"},{"key":"BFgt201087_CR45","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","volume":"76","author":"JE Rabinowitz","year":"2002","unstructured":"Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791\u2013801.","journal-title":"J Virol"},{"key":"BFgt201087_CR46","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","volume":"78","author":"G Gao","year":"2004","unstructured":"Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78: 6381\u20136388.","journal-title":"J Virol"},{"key":"BFgt201087_CR47","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1128\/jcm.29.7.1439-1446.1991","volume":"29","author":"BD Plikaytis","year":"1991","unstructured":"Plikaytis BD, Turner SH, Gheesling LL, Carlone GM . Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J Clin Microbiol 1991; 29: 1439\u20131446.","journal-title":"J Clin Microbiol"},{"key":"BFgt201087_CR48","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","volume":"60","author":"SI Rennard","year":"1986","unstructured":"Rennard SI, Basset G, Lecossier D, O\u2019Donnell KM, Pinkston P, Martin PG et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60: 532\u2013538.","journal-title":"J Appl Physiol"},{"key":"BFgt201087_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/BF03401843","volume":"7","author":"RJ Kaner","year":"2001","unstructured":"Kaner RJ, Crystal RG . Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol Med 2001; 7: 240\u2013246.","journal-title":"Mol Med"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201087","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T09:24:41Z","timestamp":1661246681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,1]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["BFgt201087"],"URL":"https:\/\/doi.org\/10.1038\/gt.2010.87","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,1]]},"assertion":[{"value":"22 July 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}